|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: P2RX4 |
Gene summary for P2RX4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | P2RX4 | Gene ID | 5025 |
| Gene name | purinergic receptor P2X 4 | |
| Gene Alias | P2X4 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q99571 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5025 | P2RX4 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.37e-05 | 4.13e-01 | -0.1954 |
| 5025 | P2RX4 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.77e-03 | 3.64e-01 | -0.1464 |
| 5025 | P2RX4 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.45e-05 | 4.15e-01 | -0.1001 |
| 5025 | P2RX4 | A015-C-203 | Human | Colorectum | FAP | 1.84e-02 | -3.08e-02 | -0.1294 |
| 5025 | P2RX4 | A002-C-205 | Human | Colorectum | FAP | 7.78e-03 | -2.84e-02 | -0.1236 |
| 5025 | P2RX4 | A015-C-006 | Human | Colorectum | FAP | 9.21e-03 | -1.82e-01 | -0.0994 |
| 5025 | P2RX4 | A002-C-114 | Human | Colorectum | FAP | 2.16e-03 | -1.61e-01 | -0.1561 |
| 5025 | P2RX4 | A015-C-104 | Human | Colorectum | FAP | 5.49e-04 | -6.73e-02 | -0.1899 |
| 5025 | P2RX4 | A002-C-016 | Human | Colorectum | FAP | 1.70e-05 | -1.83e-01 | 0.0521 |
| 5025 | P2RX4 | A002-C-116 | Human | Colorectum | FAP | 2.20e-05 | -1.66e-01 | -0.0452 |
| 5025 | P2RX4 | A018-E-020 | Human | Colorectum | FAP | 7.06e-03 | -1.26e-01 | -0.2034 |
| 5025 | P2RX4 | F034 | Human | Colorectum | FAP | 7.83e-04 | -1.72e-01 | -0.0665 |
| 5025 | P2RX4 | LZE4T | Human | Esophagus | ESCC | 9.03e-07 | 2.28e-01 | 0.0811 |
| 5025 | P2RX4 | LZE7T | Human | Esophagus | ESCC | 1.24e-02 | 1.98e-01 | 0.0667 |
| 5025 | P2RX4 | LZE24T | Human | Esophagus | ESCC | 1.76e-09 | 1.86e-01 | 0.0596 |
| 5025 | P2RX4 | LZE21T | Human | Esophagus | ESCC | 8.24e-04 | 1.97e-01 | 0.0655 |
| 5025 | P2RX4 | LZE6T | Human | Esophagus | ESCC | 7.11e-03 | 1.87e-01 | 0.0845 |
| 5025 | P2RX4 | P2T-E | Human | Esophagus | ESCC | 9.13e-52 | 7.03e-01 | 0.1177 |
| 5025 | P2RX4 | P4T-E | Human | Esophagus | ESCC | 2.33e-16 | 3.13e-01 | 0.1323 |
| 5025 | P2RX4 | P5T-E | Human | Esophagus | ESCC | 1.78e-10 | 1.61e-01 | 0.1327 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00454292 | Colorectum | FAP | positive regulation of nitric oxide biosynthetic process | 13/2622 | 40/18723 | 2.31e-03 | 1.86e-02 | 13 |
| GO:00801642 | Colorectum | FAP | regulation of nitric oxide metabolic process | 18/2622 | 64/18723 | 2.37e-03 | 1.89e-02 | 18 |
| GO:20010281 | Colorectum | FAP | positive regulation of endothelial cell chemotaxis | 7/2622 | 15/18723 | 2.40e-03 | 1.90e-02 | 7 |
| GO:19044072 | Colorectum | FAP | positive regulation of nitric oxide metabolic process | 13/2622 | 41/18723 | 2.96e-03 | 2.25e-02 | 13 |
| GO:20001911 | Colorectum | FAP | regulation of fatty acid transport | 11/2622 | 32/18723 | 3.01e-03 | 2.27e-02 | 11 |
| GO:0032306 | Colorectum | FAP | regulation of prostaglandin secretion | 6/2622 | 12/18723 | 3.24e-03 | 2.40e-02 | 6 |
| GO:0042118 | Colorectum | FAP | endothelial cell activation | 6/2622 | 12/18723 | 3.24e-03 | 2.40e-02 | 6 |
| GO:00069371 | Colorectum | FAP | regulation of muscle contraction | 37/2622 | 169/18723 | 3.39e-03 | 2.47e-02 | 37 |
| GO:00454282 | Colorectum | FAP | regulation of nitric oxide biosynthetic process | 17/2622 | 62/18723 | 4.12e-03 | 2.84e-02 | 17 |
| GO:00435001 | Colorectum | FAP | muscle adaptation | 28/2622 | 121/18723 | 4.50e-03 | 3.06e-02 | 28 |
| GO:00435423 | Colorectum | FAP | endothelial cell migration | 55/2622 | 279/18723 | 5.00e-03 | 3.33e-02 | 55 |
| GO:0055119 | Colorectum | FAP | relaxation of cardiac muscle | 7/2622 | 17/18723 | 5.62e-03 | 3.61e-02 | 7 |
| GO:0010611 | Colorectum | FAP | regulation of cardiac muscle hypertrophy | 18/2622 | 69/18723 | 5.70e-03 | 3.66e-02 | 18 |
| GO:00100384 | Colorectum | FAP | response to metal ion | 70/2622 | 373/18723 | 5.95e-03 | 3.75e-02 | 70 |
| GO:0034405 | Colorectum | FAP | response to fluid shear stress | 11/2622 | 35/18723 | 6.53e-03 | 4.05e-02 | 11 |
| GO:0015908 | Colorectum | FAP | fatty acid transport | 21/2622 | 86/18723 | 6.79e-03 | 4.17e-02 | 21 |
| GO:0014896 | Colorectum | FAP | muscle hypertrophy | 24/2622 | 104/18723 | 8.41e-03 | 4.89e-02 | 24 |
| GO:00551172 | Colorectum | FAP | regulation of cardiac muscle contraction | 19/2622 | 77/18723 | 8.67e-03 | 4.98e-02 | 19 |
| GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
| GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| P2RX4 | SNV | Missense_Mutation | rs372429881 | c.967N>A | p.Glu323Lys | p.E323K | Q99571 | protein_coding | deleterious(0.03) | possibly_damaging(0.647) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| P2RX4 | SNV | Missense_Mutation | rs759963161 | c.186G>T | p.Trp62Cys | p.W62C | Q99571 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| P2RX4 | insertion | Frame_Shift_Ins | novel | c.308_309insCGTCTCTACTAAAAATACAAAATTAGCCAGGCGTGTT | p.Asp104ValfsTer52 | p.D104Vfs*52 | Q99571 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| P2RX4 | SNV | Missense_Mutation | rs772182699 | c.1151N>A | p.Arg384Gln | p.R384Q | Q99571 | protein_coding | deleterious(0.04) | benign(0.336) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| P2RX4 | SNV | Missense_Mutation | novel | c.1139N>A | p.Arg380Lys | p.R380K | Q99571 | protein_coding | tolerated(0.25) | benign(0) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| P2RX4 | SNV | Missense_Mutation | novel | c.943N>C | p.Tyr315His | p.Y315H | Q99571 | protein_coding | tolerated(0.1) | benign(0.399) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| P2RX4 | SNV | Missense_Mutation | rs368547621 | c.1183N>A | p.Glu395Lys | p.E395K | Q99571 | protein_coding | tolerated(0.12) | benign(0.314) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| P2RX4 | SNV | Missense_Mutation | c.715N>G | p.Thr239Ala | p.T239A | Q99571 | protein_coding | tolerated(0.1) | probably_damaging(0.915) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| P2RX4 | SNV | Missense_Mutation | c.368T>C | p.Leu123Pro | p.L123P | Q99571 | protein_coding | deleterious(0.03) | possibly_damaging(0.723) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| P2RX4 | SNV | Missense_Mutation | rs566926483 | c.977N>T | p.Thr326Met | p.T326M | Q99571 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | P2X4 inhibitora | |||
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | antagonist | 336446929 | ||
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | antagonist | 336446927 | ||
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | antagonist | 336446928 | ||
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | antagonist | 178101492 | PAROXETINE | |
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | agonist | 135651446 | ADENOSINE TRIPHOSPHATE | |
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | agonist | 178100916 | ||
| 5025 | P2RX4 | ION CHANNEL, DRUGGABLE GENOME | antagonist | 135650843 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |